C

Cannabis Poland SA
WSE:CBD

Watchlist Manager
Cannabis Poland SA
WSE:CBD
Watchlist
Price: 0.301 PLN -5.94%
Market Cap: 14.8m PLN
Have any thoughts about
Cannabis Poland SA?
Write Note

Net Margin
Cannabis Poland SA

-679.2%
Current
-898%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-679.2%
=
Net Income
-2m
/
Revenue
287.8k

Net Margin Across Competitors

Country Company Market Cap Net
Margin
PL
Cannabis Poland SA
WSE:CBD
14.8m PLN
-679%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-79%
US
Eli Lilly and Co
NYSE:LLY
756.2B USD
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
35%
US
Johnson & Johnson
NYSE:JNJ
351.2B USD
17%
US
Merck & Co Inc
NYSE:MRK
251.2B USD
19%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
20%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
13%
CH
Novartis AG
SIX:NOVN
171.5B CHF
35%
US
Pfizer Inc
NYSE:PFE
151.1B USD
7%
Country PL
Market Cap 14.8m PLN
Net Margin
-679%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 756.2B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 351.2B USD
Net Margin
17%
Country US
Market Cap 251.2B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 151.1B USD
Net Margin
7%
No Stocks Found

Cannabis Poland SA
Glance View

Market Cap
14.8m PLN
Industry
Pharmaceuticals

Cannabis Poland SA engages in the production and distribution of cannabinoid vaporization equipment and oils. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2013-04-09. The firm focuses on operating in the field of production and sale of pharmaceutical and medical products, with the main focus on vaporization products containing cannabinoids manufactured from cannabis. The firm also expands its activity to include other products than pharmaceuticals, such as cosmetics, oils containing cannabinoids for human and animals and photovoltaic cells. The firm is engaged in research and development of a Cannabidiol (CBD)/ Tetrahydrocannabinol-based (THC-based) pharmaceutical for use in the treatment of seizures associated with drug-resistant epilepsy.

CBD Intrinsic Value
0.016 PLN
Overvaluation 95%
Intrinsic Value
Price
C

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-679.2%
=
Net Income
-2m
/
Revenue
287.8k
What is the Net Margin of Cannabis Poland SA?

Based on Cannabis Poland SA's most recent financial statements, the company has Net Margin of -679.2%.